Clinical and endoscopic healing after infliximab treatment in patients with Crohn's disease

Digestive Endoscopy

Volumn 18, Issue 1, 2006, Pages 29-33

  Sou, Suketo ^a   Matsui, Toshiyuki ^a   Yao, Tsuneyoshi ^a   Yorioka, Makoto ^a   Tsuda, Sumio ^a   Kikuchi, Yosuke ^a   Wada, Yoko ^a   Nagahama, Takashi ^a   Yao, Kenshi ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Crohn's disease; Endoscopy; Infliximab; Mucosal healing

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON ULCER; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFECT; ENDOSCOPIC THERAPY; FEMALE; HUMAN; ILEUM; INTESTINE STENOSIS; MALE; MORPHOLOGY; POLYPOSIS; TREATMENT OUTCOME;

EID: 32944472801     PISSN: 09155635     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2006.00566.x     Document Type: Article

References (18)

1. D'Haens G, Deventer SV, Hogezand RV et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
2. Furukawa H, Yamada M, Sakurai T et al. Enteral nutrition and total parenteral nutrition in Crohn's disease: factors influencing induction of remission. Nippon Shokakibyo Gakkai Zasshi 1997; 94: 813-25 (in Japanese with English Abstract).
3. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
4. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N. Engl. J. Med. 1997; 337: 1029-35.
5. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
6. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
7. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am. J. Gastroenterol. 2000; 95: 3469-77.
8. Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am. J. Gastroenterol. 2000; 95: 3490-7.
9. Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the 100 patients. Am. J. Gastroenterol. 2001; 96: 722-9.
10. Arnott ID, McDonald D, Williams A et al. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 2001; 15: 1639-46.
11. Asakura H, Yao T, Matsui T et al. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 2001; 16: 763-9.
12. Arslan S, Kav T, Besisik F et al. Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 2003; 50: 952-6.
13. Gheorghe L, Gheorghe C, Badea M et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania. Rom. J. Gastroenterol. 2003; 12: 7-13.
14. Derkx B, Taminiau J, Radema S et al. Tumor-necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
15. Sandborn WJ, Feagan BG, Hanaure SB et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30.
16. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2002; 17: S176-85.
17. Sanborn WJ, Hanaure SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. 2002; 97: 2962-72.
18. Kinney T, Rawlins M, Kozarek R et al. Immunomodulators and 'on demand' therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am. J. Gastroenterol. 2003; 98: 608-12.